CSL Dirección

Dirección controles de criterios 4/4

El CEO de CSL's es Paul McKenzie , nombrado en Mar 2023, tiene una permanencia de 1.08 años. compensación anual total es $4.41M, compuesta por 29% salario y 71% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.005% de las acciones de la empresa, por valor de A$6.19M. La antigüedad media del equipo directivo y de la junta directiva es de 4.4 años y 4.3 años, respectivamente.

Información clave

Paul McKenzie

Chief Executive Officer (CEO)

US$4.4m

Compensación total

Porcentaje del salario del CEO	29.0%
Permanencia del CEO	1.2yrs
Participación del CEO	0.005%
Permanencia media de la dirección	4.5yrs
Promedio de permanencia en la Junta Directiva	4.4yrs

Actualizaciones recientes de la dirección

Recent updates

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

May 01

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

Aug 13

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

May 30

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

May 09

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Mar 01

Estimating The Fair Value Of CSL Limited (ASX:CSL)

Feb 07

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Nov 17

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Oct 27

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Aug 19

Is CSL Limited (ASX:CSL) Trading At A 22% Discount?

Jul 29

CSL's (ASX:CSL) Problems Go Beyond Weak Profit

Feb 22

Is CSL Limited (ASX:CSL) Worth AU$270 Based On Its Intrinsic Value?

Jan 19

With EPS Growth And More, CSL (ASX:CSL) Is Interesting

Dec 08

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Oct 26

We Think Shareholders Will Probably Be Generous With CSL Limited's (ASX:CSL) CEO Compensation

Oct 05

Here's Why We Think CSL (ASX:CSL) Is Well Worth Watching

Sep 02

CSL Limited (ASX:CSL) Shares Could Be 30% Above Their Intrinsic Value Estimate

Jul 22

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

Jul 01

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Paul McKenzie en comparación con los beneficios de CSL?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	US$2b
Sep 30 2023	n/a	n/a	US$2b
Jun 30 2023	US$4m	US$1m	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	US$5m	US$965k	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	US$6m	US$989k	US$2b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	n/a	n/a	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	US$7m	US$1m	US$2b

Compensación vs. Mercado: La compensación total ($USD4.41M) de Paul está en línea con el promedio de empresas de tamaño similar en el mercado Australian ($USD4.04M).

Compensación vs. Ingresos: La compensación de Paul ha sido consistente con los resultados de la empresa en el último año.

CEO

Paul McKenzie (57 yo)

1.2yrs

Permanencia

US$4,409,610

Compensación

Dr. Paul F. McKenzie, Ph.D. (Chemical Engineering), has been Chief Operating Officer at CSL Behring LLC since 2019. Dr. McKenzie serves as Chief Operating Officer at CSL Plasma Inc. Dr. McKenzie had been C...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul McKenzie	MD, CEO & Executive Director	1.2yrs	US$4.41m	0.0046% $ 6.2m
Joy Linton	Chief Financial Officer	3.2yrs	US$3.31m	0.0024% $ 3.2m
Mark Dehring	Head of Investor Relations	no data	sin datos	sin datos
Gregory Boss	Executive VP of Legal & General Counsel	15.3yrs	US$2.31m	sin datos
Christina Hickie	Senior Manager of Communications	no data	sin datos	sin datos
Roanne Parry	Chief Human Resources Officer	less than a year	sin datos	sin datos
Karen Etchberger	Executive Vice President of Quality & Business Services	14.1yrs	US$2.14m	sin datos
Jemimah Brennan	Head of Communications - Asia Pacific	no data	sin datos	sin datos
Andrew Nash	Senior Vice President of Research	no data	sin datos	sin datos
William Mezzanotte	Executive VP & Head of Research and Development	5.6yrs	US$2.14m	sin datos
Stephen Marlow	Senior VP & GM of Seqirus	5.3yrs	sin datos	sin datos
Mark Hill	Chief Digital Information Officer & Executive VP	3.6yrs	sin datos	sin datos

4.5yrs

Permanencia media

61yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CSL se considera experimentado (4.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul McKenzie	MD, CEO & Executive Director	1.4yrs	US$4.41m	0.0046% $ 6.2m
Megan Clark	Independent Non Executive Director	8.3yrs	US$242.27k	0.0011% $ 1.4m
Alison Watkins	Independent Non-Executive Director	2.8yrs	US$213.24k	0.00073% $ 977.4k
Carolyn Hewson	Independent Non-Executive Director	4.4yrs	US$234.27k	0.00043% $ 575.7k
Brian McNamee	Independent Non-Executive Chairman	6.3yrs	US$601.22k	0.026% $ 35.0m
Robert Cuthbertson	Non-Independent Non-Executive Director	5.6yrs	US$220.29k	0.015% $ 19.5m
Duncan Maskell	Independent Non-Executive Director	2.8yrs	US$187.33k	0.00028% $ 374.9k
Marie McDonald	Independent Non-Executive Director	10.8yrs	US$213.87k	0.00086% $ 1.2m
Samantha Lewis	Director	less than a year	sin datos	0.00039% $ 522.2k

4.4yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de CSL se considera experimentada (4.3 años de antigüedad promedio).

CSL Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

Recent updates

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL Limited's (ASX:CSL) Earnings Haven't Escaped The Attention Of Investors

Now 21% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Is CSL (ASX:CSL) Using Too Much Debt?

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

CSL Limited (ASX:CSL) Shares Could Be 28% Below Their Intrinsic Value Estimate

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

These 4 Measures Indicate That CSL (ASX:CSL) Is Using Debt Reasonably Well

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

Upcoming dividend of US$1.07 per share at 1.1% yield

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

Estimating The Fair Value Of CSL Limited (ASX:CSL)

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Independent Non Executive Director recently bought AU$74k worth of stock

Consensus forecasts updated

Now 20% undervalued

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Now 20% undervalued

MD, CEO & Executive Director exercised options and sold AU$4.7m worth of stock

Non-Independent Non-Executive Director recently sold AU$6.4m worth of stock

Upcoming dividend of US$1.18 per share

Non-Independent Non-Executive Director exercised options to buy AU$11m worth of stock.

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

Now 20% undervalued

Is CSL Limited (ASX:CSL) Trading At A 22% Discount?

Now 20% undervalued after recent price drop

Upcoming dividend of US$1.04 per share

Independent Non-Executive Chairman exercised options to buy AU$74k worth of stock.

Independent Non-Executive Director recently bought AU$54k worth of stock

CSL's (ASX:CSL) Problems Go Beyond Weak Profit

First half 2022 earnings: EPS and revenues exceed analyst expectations